These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28333664)

  • 21. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A; Schubert S
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes.
    Kang YA; Shim TS; Koh WJ; Lee SH; Lee CH; Choi JC; Lee JH; Jang SH; Yoo KH; Jung KH; Kim KU; Choi SB; Ryu YJ; Kim KC; Um S; Kwon YS; Kim YH; Choi WI; Jeon K; Hwang YI; Kim SJ; Lee HK; Heo E; Yim JJ
    Ann Am Thorac Soc; 2016 Mar; 13(3):364-70. PubMed ID: 26871879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.
    Ghazi I; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2016 Nov; 73(21):1769-1776. PubMed ID: 27769972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Commonly used fluoroquinolones cross-react with urine drug screens for opiates, buprenorphine, and amphetamines.
    Colby JM; Patel PC; Fu DY; Rutherford NJ
    Clin Biochem; 2019 Jun; 68():50-54. PubMed ID: 30991036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Mar; 51(5):672-8. PubMed ID: 8203388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration.
    Kondo M; Yoshida N; Yoshida M; Tanaka C; Tagami T; Horikawa K; Sugaya K; Takase H
    Am J Health Syst Pharm; 2023 Jan; 80(1):e53-e58. PubMed ID: 36094564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.
    Jim LK
    Ann Pharmacother; 1993 Jun; 27(6):704-7. PubMed ID: 8329786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
    Cochran BG; Sowinski KM; Fausel C; Overholser BR
    Am J Health Syst Pharm; 2007 Jul; 64(13):1410-4. PubMed ID: 17592007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Feb; 51(4):495-9. PubMed ID: 8017415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
    Fukuda M; Yamada M; Kinoshita S; Inatomi T; Ohashi Y; Uno T; Shimazaki J; Satake Y; Maeda N; Hori Y; Nishida K; Kubota A; Nakazawa T; Shimomura Y
    Adv Ther; 2012 Apr; 29(4):339-49. PubMed ID: 22529026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compatibility of amiodarone hydrochloride with vasopressin during simulated Y-site administration.
    Ramaley CC; Li F; Du C
    Int J Pharm Compd; 2013; 17(5):436-8. PubMed ID: 24459790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration.
    Kidd JM; Avery LM; Asempa TE; Nicolau DP; Kuti JL
    Clin Ther; 2018 Feb; 40(2):261-269. PubMed ID: 29290374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions.
    Wilder AG; Foushee JA; Fox LM; Navalle J; Wright AM; Greer MA
    Int J Pharm Compd; 2020; 24(3):238-241. PubMed ID: 32401743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
    Correard F; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Am J Health Syst Pharm; 2014 Aug; 71(15):1288-91. PubMed ID: 25027536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of toxicities of moxifloxacin, cefuroxime, and levofloxacin to corneal endothelial cells in vitro.
    Haruki T; Miyazaki D; Matsuura K; Terasaka Y; Noguchi Y; Inoue Y; Yamagami S
    J Cataract Refract Surg; 2014 Nov; 40(11):1872-8. PubMed ID: 25262563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated y-site administration.
    Ben M; Trusley C; Kupiec TC; Trissel LA
    Int J Pharm Compd; 2008; 12(4):368-71. PubMed ID: 23969774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones.
    Walbrown MA; Aspinall SL; Bayliss NK; Stone RA; Cunningham F; Squier CL; Good CB
    J Manag Care Pharm; 2008; 14(1):34-40. PubMed ID: 18240880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
    Trissel LA; Saenz CA; Ogundele AB; Ingram DS
    Am J Health Syst Pharm; 2004 Nov; 61(21):2289-93. PubMed ID: 15552637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.